Abstract:6065 Background: Despite intensive therapy, 30% of patients (pts) with LA-HNSCC relapse. Published data shows that MRD detection during follow up (FU) may predict relapse, e.g. human papillomavirus (HPV) DNA in p16+ pts post radiation (RT) or chemoradiation (CRT); or circulating tumor DNA (ctDNA) post surgery. MRD detection using multiple assays after definitive RT/CRT has not been reported. Methods: We enrolled pts with high risk LA-HNSCC (stage III HPV+, III-IVB HPV-) treated with curative intent: surgery ± adjuvant therapy, RT or CRT. Plasma was collected pre-treatment at baseline (B), at 4-6 weeks (FU1) and 8-12 weeks (FU2) post-treatment. RaDaR, a personalized liquid biopsy assay that targets patient specific somatic variants identified in whole exome sequencing (WES) from matched tumor tissue, was used to detect ctDNA, reported as estimated Variant Allele Fraction (eVAF). Cancer Personalized Profiling by deep sequencing (CAPP-seq) was used as a tumor naïve assay for ctDNA, reported as mean VAF. HPV sequencing (HPV-seq) in all and digital PCR (dPCR) in p16+ pts were used to detect HPV DNA. Relapse free survival (RFS) was estimated using Kaplan Meier and associations of ctDNA or HPV DNA with RFS using log-rank test. Assays were compared with Spearman correlation. Results: A total of 89 plasma samples from 35 pts were collected prospectively; 32 pts with at least a FU sample were evaluable: 26 had both. Median age was 63 years (34-71). Most pts were stage III HPV + (N = 16, 50%) and received CRT (N = 25, 78%). No pts had clinical or radiological residual disease at FU2. Median FU was 18.3 months (5.1-25.9), there were 7 clinical relapses. RaDar was applied in 17 pts with WES in matched tissue, including 6 with relapse. ctDNA at B was detected in 15/17 (88%). eVAF at B was not associated with RFS (p = 0.98). Two pts relapsed < 1 year after RT/CRT and had eVAF > 0.001% in FU2 sample; lead time to relapse was 100 and 245 days. FU1 sample of a pt who relapsed > 1 year post-CRT was close to the threshold for ctDNA+ with eVAF 0.0001%; lead time was 494 days. Three pts who received CRT relapsed > 500 days from FU2 sample (ctDNA-). CAPP-seq was applied to 29 pts; mean VAF correlated with eVAF at B (r = 0.75) but not at FU. ctDNA+ at FU using CAPP-seq was not associated with RFS (p = 0.25). HPV-seq was applied to 32 pts; specificity and sensitivity was 100% at B. Among p16+ pts with FU sample (N = 15), HPV DNA was detected in 4/4 with relapse and not in those without, predicting shorter RFS (p < 0.01). dPCR detected HPV DNA in 2/4 pts with relapse. HPV-seq and dPCR correlation was high at B (r = 0.99), lower at FU2 (r = 0.66). Conclusions: HPV DNA and ctDNA can be detected in LA-HNSCC before and after definitive therapy. RaDaR but not CAPP-seq may detect MRD in pts who relapse within 1 year after RT/CRT with a significant lead time. HPV-seq may be more sensitive than dPCR to detect HPV DNA in MRD. Validation in an interception study is planned (NCT 04599309 ).

Utilization of Personalized Tumor-Specific Methylation Haplotypes of Circulating DNA to Monitor Minimal Residual Disease in Patients with Hepatocellular Carcinoma Undergoing Curative Resection.

Prognostic value of minimal residual disease profiling in resectable hepatocellular carcinoma.

Personalized MRD Assessment in Peri-surgical ctDNA for Prognostic Prediction in Hepatocellular Carcinoma

Utilization of Tumor-Informed Circulating Tumor DNA in Detecting Minimal Residual Disease and Guiding Adjuvant Therapy in Liver Cancer.

Ultra-sensitive Baseline-Informed MRD Assay to Predict Prognosis Outcomes in Patients with Resectable Hepatocellular Carcinoma.

Abstract 1020: Tissue-informed ctDNA MRD assay detects post-surgery minimal residual disease in HCC patients

Longitudinal and Personalized Detection of Circulating Tumor DNA (ctdna) for Monitoring Efficacy of Atezolizumab Plus Bevacizumab in Patients with Unresectable Hepatocellular Carcinoma (HCC).

Application of circulating tumor DNA for prediction and surveillance of tumor recurrence after liver transplantation: A pilot study.

Circulating Tumor DNA Correlates with Microvascular Invasion and Predicts Tumor Recurrence of Hepatocellular Carcinoma

Potential Utility of Methylation Levels Detected from Circulating Tumor DNA (ctdna) in Predicting Molecular Residual Disease (MRD) in Patients with Resected Non-Small Cell Lung Cancer (NSCLC).

Tumor Mutational Burden from Circulating Tumor DNA Predicts Recurrence of Hepatocellular Carcinoma After Resection: An Emerging Biomarker for Surveillance

Plasma cell-free DNA methylomes for hepatocellular carcinoma detection and monitoring after liver resection or transplantation

Enhanced detection of molecular residual disease (MRD) by tumor-informed and tumor-agnostic variants in circulating tumor DNA (ctDNA).

Analytical and clinical validation of a personalized, tumor-informed circulating tumor DNA assay for minimal residual disease detection.

Dynamic monitoring of circulating tumor DNA to predict prognosis and efficacy of adjuvant chemotherapy after resection of colorectal liver metastases

Effect of dynamic circulating tumor DNA minimal residual disease detection on recurrence surveillance and second resection rate after curative intent resection of colorectal liver metastasis: A prospective cohort study.

Personalized circulating tumor DNA monitoring improves recurrence surveillance and management after curative resection of colorectal liver metastases: A prospective cohort study

Tracking MRD and Neoantigen Targets Using a Tumor-Informed Liquid Biopsy Platform in HCC Patients Treated with Personalized Cancer Vaccine and Pembrolizumab.

Utilization of cell-free DNA fragmentomics in minimal residual disease detection for non-small cell lung cancer.

Serial Circulating Tumor DNA to Predict Early Recurrence in Patients with Hepatocellular Carcinoma: a Prospective Study.

Multimodal Detection in Plasma of Molecular Residual Disease (MRD) in Locally Advanced Head and Neck Squamous Cell Carcinoma (LA-HNSCC).